News about 'TB Treatment'

The first detailed study of the private tuberculosis (TB) drug market, published on May 4 th , in the PLoS ONE journal, finds that the market is surprisingly large, and has irregular practices that could be driving treatment failures and contributing to the emergence of multidrug-resistant TB (MDR-...

Dr. Mark Cotton is Director of Children’s Infectious Diseases Clinical Research Unit (KID-CRU) at University of Stellenbosch in Cape Town, South Africa. Pediatric TB has emerged as a broad priority only in more recent years, though the University of Stellenbosch / Tygerberg Hospital team has been...

Lienhardt C, Cook SV, Burgos M, Yorke-Edwards V, Rigouts L, Anyo G, Kim SJ, Jindani A, Enarson DA, Nunn AJ; Study C Trial Group. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled...

Monedero I, Caminero JA. Evidence for promoting fixed-dose combination drugs in tuberculosis treatment and control: a review. Int J Tuberc Lung Dis. 2011 Apr;15(4):433-9. In this week’s article, Monedero and Caminero conduct a critical review of research on the use of fixed-dosed combinations (FDCs...

Frigati LJ, Kranzer K, Cotton MF, Schaaf HS, Lombard CJ, Zar HJ. The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting. Thorax. 2011 Apr 2. [Epub ahead of print] This week, the focus is on...

The following is an e-mail circulated on the Stop TB Advocacy Network from a TB patient named Pervaiz Tufail, location unknown. It is a powerful message from the patient’s perspective. Subject: TODAY IS WORD TB DAY BUT WHERE AM I? I heard Akram died of TB today, last week Rizwan died and I am...

Today on World TB Day, the International Scientific Exchange Foundation of China (ISEFC) , announced the signing of a Memorandum of Understanding with the Global Alliance for TB Drug Development (TB Alliance) to establish the Global Health R&D Center of China (GHRC). This innovative center will...

The Médecins Sans Frontières and The Union will release on World TB Day a new report entitled “DR-TB drugs under the microscope” outlining drugs currently available to treat drug-resistant tuberculosis (DR-TB) including product information, sources of the drug, quality status, and price. The...

Chen TC, Lu PL, Lin CY, Lin WR, Chen YH. Fluoroquinolones are associated with delayed treatment and resistance in tuberculosis: a systematic review and meta-analysis. Int J Infect Dis. 2011 Mar;15(3):e211-6. Epub 2010 Dec 30. Chen, et al., conducted a meta-analysis to ascertain the answer to two...

[wpaudio url=”/blog/media/podcasts/Andersen_Peter_finished.mp3″ text=”Click here to play the Peter Anderson Podcast” dl=”0″] Summary: Dr. Peter Andersen is Vice President of Vaccine Research and Development at Statens Serum Institut (SSI). The WGND had the opportunity to talk with Dr. Andersen on a...

Chemical Structure of Pyrazinamide Ahmad Z, Fraig MM, Bisson GP, Nuermberger EL, Grosset JH, Karakousis PC. Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis. Antimicrob Agents Chemother. 2011 Jan 31. [Epub ahead of print] First discovered as...

This is part three of our interview with Dr. Hesseling. Click here to view part one . Click here to view part two . Dr. Anneke Hesseling is the Director of the Paediatric TB Research Program at the Desmond Tutu TB Centre at Stellenbosch University in Cape Town, South Africa. She has South African...

This is part two of our interview with Dr. Hesseling. Click here to view part one . Dr. Anneke Hesseling is the Director of the Paediatric TB Research Program at the Desmond Tutu TB Centre at Stellenbosch University in Cape Town, South Africa. She has South African and US training in Medicine and...

Saunders NJ, Urmi HT, Thomson ML, Doig C, Laurenson IF, Blaxter ML. Stepwise mutation to multiple drug resistance in Mycobacterium tuberculosis in an otherwise stable genetic backgrounddoes not support models of high mutation in the host and emphasizes the need for maintained effective...

Several news agencies reported on an article that appeared in the Canadian Medical Association Journal showing an increase risk of serious side-effects for patients over 65 years old being treated for latent tuberculosis. Compared to untreated patients matched by age, patients 65 years old being...